FDA committee recommends approval for BioMarin's Vimizim

20 November 2013
fda-big

A US Food and Drug Administration panel has voted in favor of approval of Vimizim (BMN-110, elosulfase alfa) for the treatment of Morquio A syndrome from USA-based rare disease drug developer BioMarin Pharmaceuticals (Nasdaq: BMRN).

The Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 20 to one in favor for use in all Morquio A syndrome patients, also called Mucopolysaccharidosis Type IVA (MPS IVA). One voted in favor of approval for a subgroup of MPS IVA patients, and one panel member voted to not recommend approval. The committee additionally voted 16-five that no safety concerns were associated with the enzyme replacement therapy.

Could achieve sales of over $500 million in 2018

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical